Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $64.78

Janux Therapeutics, Inc. (NASDAQ:JANX)’s share price gapped down prior to trading on Monday . The stock had previously closed at $64.78, but opened at $63.16. Janux Therapeutics shares last traded at $58.63, with a volume of 209,126 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Janux Therapeutics in a research report on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. BTIG Research assumed coverage on Janux Therapeutics in a research report on Thursday, March 21st. They set a “buy” rating and a $62.00 price objective for the company. Bank of America increased their target price on Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th. Finally, Jonestrading assumed coverage on shares of Janux Therapeutics in a report on Tuesday, April 16th. They set a “buy” rating and a $70.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $61.33.

Janux Therapeutics Stock Down 3.6 %

The business’s 50 day moving average is $45.03 and its two-hundred day moving average is $22.15. The firm has a market capitalization of $3.08 billion, a P/E ratio of -45.90 and a beta of 3.87.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The business had revenue of $2.46 million during the quarter, compared to analysts’ expectations of $0.98 million. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

Large investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in Janux Therapeutics by 25.5% in the 3rd quarter. FMR LLC now owns 6,351,322 shares of the company’s stock valued at $64,021,000 after buying an additional 1,288,526 shares during the period. RA Capital Management L.P. increased its stake in shares of Janux Therapeutics by 5.7% during the 3rd quarter. RA Capital Management L.P. now owns 9,165,652 shares of the company’s stock worth $92,390,000 after purchasing an additional 495,008 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Janux Therapeutics by 27.8% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock valued at $11,592,000 after purchasing an additional 250,000 shares in the last quarter. Cerity Partners LLC acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at $654,000. Finally, Capstone Investment Advisors LLC acquired a new stake in shares of Janux Therapeutics in the 1st quarter valued at $1,969,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.